Skip to main content
Publications
Forns J , Dudukina E, Hagg D, Szentkuti P, Gembert K, Plana E , Gilsenan A , Horvath-Puho E, Ehrenstein V, Reutfors J, Rebordosa C . Risk of major cardiovascular and cerebrovascular events in users of lisdexamfetamine and other medications for attention-deficit/hyperactivity disorder in Denmark and Sweden: a population-based cohort study . Neurol Ther. 2022 Dec 1;11(4):1659-76. doi: 10.1007/s40120-022-00396-y
Forns J , Dudukina E, Hagg D, Szentkuti EP, Gembert K, Plana E , Gilsenan A , Horvath-Puho E, Reutfors J, Rebordosa C . Cohort study of the incidence of major cardiovascular events in new adult users of lisdexamfetamine and remote adult users of other attention-deficit/hyperactivity disorder treatments . Poster presented at the 2021 8th World Congress on ADHD Virtual Event; May 6, 2021.
Gilsenan AW . Depression and pain in the primary care setting . Presented at the Correlation Between Depression and Pain: Creating a New Treatment Paradigm to Evaluate Cost and Caliber of Care. Symposia at the Academy of Managed Care Pharmacy 2002 Educational Conference; October 2002. Washington, DC.
Kroenke K, West SL, Swindle R, Gilsenan A , Eckert GJ, Dolor R, Stang P, Zhou XH, Hays R, Weinberger M. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial . JAMA. 2001 Dec 19;286(23):2947-55.